Abstract
Sixteen patients with stage III multiple myeloma (MM) and a median age of 51 years were treated with autografting followed by reduced intensity conditioning allotransplantation (RICT). Nine patients are alive in remission at a median of 30 months after their transplants, one patient is alive in relapse and 6 patients died of progressive disease (5) or extensive chronic graft-versus-host disease, infections and progressive disease (1). We suggest that this two-step approach is feasible and it has strong anti-myeloma activity.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / pharmacology
-
Disease Progression
-
Disease-Free Survival
-
Feasibility Studies
-
Female
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / mortality
-
Graft vs Host Disease / prevention & control
-
Granulocyte Colony-Stimulating Factor / pharmacology
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Infections / etiology
-
Infections / mortality
-
Male
-
Melphalan / therapeutic use
-
Middle Aged
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / therapy*
-
Peripheral Blood Stem Cell Transplantation / methods*
-
Postoperative Complications / mortality
-
Remission Induction
-
Salvage Therapy
-
Survival Analysis
-
Transplantation Conditioning / methods*
-
Transplantation, Autologous / methods*
-
Transplantation, Homologous / methods*
-
Treatment Outcome
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
-
Whole-Body Irradiation
Substances
-
Immunosuppressive Agents
-
Granulocyte Colony-Stimulating Factor
-
Cyclophosphamide
-
Vidarabine
-
fludarabine
-
Melphalan